In vivo experimentation in appropriate models will be required to determine what level of mucus transport will afford clinical benefit to CF patients , but we predict that a future goal for corrective gene transfer to the CF human airways in vivo would attempt to target at least 25 % of surface epithelial cells to achieve mucus transport rates comparable to those in non - CF airways .